Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been given an average rating of “Moderate Buy” by the thirteen research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $10.4167.

TSHA has been the subject of several research reports. UBS Group set a $11.00 target price on Taysha Gene Therapies in a research note on Thursday, December 4th. Wall Street Zen downgraded shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Citizens Jmp lifted their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “market outperform” rating in a research note on Wednesday, November 5th. Raymond James Financial began coverage on shares of Taysha Gene Therapies in a report on Tuesday, October 21st. They issued a “strong-buy” rating and a $13.00 target price on the stock. Finally, Robert W. Baird raised their target price on shares of Taysha Gene Therapies from $7.00 to $12.00 and gave the stock an “outperform” rating in a report on Thursday, October 2nd.

Taysha Gene Therapies Trading Up 4.7%

Taysha Gene Therapies stock opened at $5.56 on Thursday. Taysha Gene Therapies has a 12-month low of $1.05 and a 12-month high of $5.64. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48. The stock has a market capitalization of $1.52 billion, a PE ratio of -16.85 and a beta of 1.06. The firm has a 50 day simple moving average of $4.66 and a 200-day simple moving average of $3.43.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. As a group, equities research analysts expect that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 260,047 shares of the business’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $4.51, for a total transaction of $1,172,811.97. Following the sale, the insider directly owned 1,006,439 shares of the company’s stock, valued at $4,539,039.89. The trade was a 20.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.78% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of institutional investors have recently bought and sold shares of TSHA. Jefferies Financial Group Inc. lifted its position in shares of Taysha Gene Therapies by 4,105.3% in the 2nd quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock valued at $23,825,000 after acquiring an additional 10,068,479 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in Taysha Gene Therapies during the 2nd quarter valued at $11,178,000. Barclays PLC lifted its holdings in shares of Taysha Gene Therapies by 1,042.8% in the third quarter. Barclays PLC now owns 5,148,112 shares of the company’s stock valued at $16,834,000 after purchasing an additional 4,697,611 shares in the last quarter. MPM Bioimpact LLC acquired a new stake in shares of Taysha Gene Therapies in the second quarter worth $6,823,000. Finally, Vestal Point Capital LP grew its holdings in shares of Taysha Gene Therapies by 83.3% during the third quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company’s stock valued at $17,985,000 after buying an additional 2,500,000 shares in the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.